Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: A national multicenter study.

Date publication

mars 2021

Journal

Rheumatology (Oxford, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AUBIN François , Dr NARDIN Charlée

Tous les auteurs :
Weill A, Delyon J, Descamps V, Deschamps L, Dinulescu M, Dupuy A, Célérier P, Nardin C, Aubin F, Le Corre Y, Heidelberger V, Maubec E, Malissen N, Longvert C, Machet L, Gounant V, Brosseau S, Bonniaud B, Jeudy G, Psimaras D, Doucet L, Lebbe C, Zalcman G, De Masson A, Baroudjian B, Leonard-Louis S, Hervier B, Brunet-Possenti F,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33725115

Résumé

The occurrence of immune-related myositis (irM) is increasing, yet there are no therapeutic guidelines. We sought to analyze the current therapeutic strategies of irM and evaluate the outcomes of immune checkpoint inhibitors (ICI) rechallenge.

Mots clés

cancer, dermatomyositis, immune checkpoint inhibitors, immune-related adverse events, myositis

Référence

Rheumatology (Oxford). 2021 Mar 16;: